Drug‐Loaded Bacillus Calmette–Guérin Bacteria for Immuno‐Chemo Combo Therapy in Bladder Cancer
Advanced Materials · 2024-05 · 36 (19)
DOI: 10.1002/adma.202310735 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 16.02.2024. Verfasst von Kangkang Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Doxorubicin, Immunotherapy. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Scientific and Technological Research Program of Tianjin Municipal Education Commission, Scientific and Technological Research Program of Tianjin Health Commission.
Abstract (Originalsprache)
Intravesical Bacillus Calmette–Guérin (BCG) is a well‐established strategy for managing high‐risk nonmuscle‐invasive bladder cancer (NMIBC); however, over half of patients still experience disease recurrence or progression. Although the combined intravesical instillation of various chemotherapeutic drugs is implemented in clinical trials to enhance the BCG therapy, the outcome is far from satisfying due to severe irritative effects and treatment intolerance at high doses. Therefore, it is adopted the “biotin–streptavidin strategy” to doxorubicin (DOX)‐encapsulated nanoparticles within live BCG bacteria (DOX@BCG) to improve treatment outcomes. Adherence of BCG to the bladder epithelium helps precisely target DOX@BCG to the local tumor cells and simultaneously increases intratumoral transport of therapeutic drugs. DOX@BCG effectively inhibits cancer progression and prolongs the survival of rats/mice with orthotopic bladder cancer owing to synergism between BCG‐immunotherapy, DOX‐chemotherapy, and DOX‐induced immunogenic tumor cell death; furthermore, it exhibits improved tolerance and biosafety, and establishes antitumor immunity in the tumor microenvironment. Therefore, the drug‐loaded live BCG bacterial delivery system holds considerable potential for clinical translation in the intravesical treatment of bladder cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
- Department of Radiology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
ORCID-Profile: Yang Zhao
Förderung
- National Natural Science Foundation of China
- Scientific and Technological Research Program of Tianjin Municipal Education Commission
- Scientific and Technological Research Program of Tianjin Health Commission
- Scientific Research Project of Municipal Education Commission
- Natural Science Foundation of Tianjin Municipality
- Science Fund for Distinguished Young Scholars of Tianjin Municipality
- Tianjin Key Medical Discipline (Specialty) Construction Project
Zitieren
APA
Liu, K., Wang, L., Peng, J., Lyu, Y., Li, Y., Duan, D., Zhang, W., Wei, G., Li, T., Niu, Y., & Zhao, Y. (2024). Drug‐Loaded Bacillus Calmette–Guérin Bacteria for Immuno‐Chemo Combo Therapy in Bladder Cancer. Advanced Materials, 36(19). https://doi.org/10.1002/adma.202310735
Vancouver
Liu K, Wang L, Peng J, Lyu Y, Li Y, Duan D, et al. Drug‐Loaded Bacillus Calmette–Guérin Bacteria for Immuno‐Chemo Combo Therapy in Bladder Cancer. Advanced Materials. 2024;36(19). doi:10.1002/adma.202310735
BibTeX
@article{Liu2024,
author = {Liu, Kangkang and Wang, Lining and Peng, Jing and Lyu, Yuanji and Li, Yiming and Duan, Dengyi and Zhang, Wenyi and Wei, Guojiang and Li, Taipeng and Niu, Yuanjie and Zhao, Yang},
title = {Drug‐Loaded Bacillus Calmette–Guérin Bacteria for Immuno‐Chemo Combo Therapy in Bladder Cancer},
journal = {Advanced Materials},
year = {2024},
volume = {36},
number = {19},
doi = {10.1002/adma.202310735}
}
EUVIMED